ZyVersa Therapeutics, Inc. (ZVSA)
NASDAQ: ZVSA · Real-Time Price · USD
0.5180
-0.0218 (-4.04%)
At close: May 13, 2025, 4:00 PM
0.5153
-0.0027 (-0.52%)
Pre-market: May 14, 2025, 6:20 AM EDT

ZyVersa Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-8.84-9.41-98.3-14.12-8.08-12.68
Depreciation & Amortization
00.010.010.010.010.01
Other Amortization
---0.040.320.29
Asset Writedown & Restructuring Costs
--93.33---
Stock-Based Compensation
0.550.711.193.584.143.68
Other Operating Activities
0.210.21-7.56-0.05-0.440.49
Change in Accounts Payable
1.250.752.414.54-0.31-0.6
Change in Other Net Operating Assets
1.280.180.191.12-0.713.71
Operating Cash Flow
-5.56-7.56-8.72-4.89-5.08-5.11
Long-Term Debt Issued
----5.231.69
Net Debt Issued (Repaid)
----5.231.69
Issuance of Common Stock
5.876.5419.08--3.02
Repurchase of Common Stock
---0.01---
Other Financing Activities
-0.74-0.59-2.42-0.1--0.14
Financing Cash Flow
5.135.955.961.875.234.56
Net Cash Flow
-0.42-1.61-2.76-3.020.15-0.55
Levered Free Cash Flow
-2.03-4.09-5.46-1.65-2.02-
Unlevered Free Cash Flow
-1.79-3.92-5.46-1.43-1.83-
Change in Net Working Capital
-2.79-1.08-2.35-3.631.27-
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q